Lupin Obtains Multiple Legacy Brands from Menarini
Deal comes amid previous exclusive marketing agreement.
Lupin revealed that it has inked an agreement with Menarini to acquire five of its legacy brands in strategic therapy. Including the areas of gastroenterology, urology, and anti-infectives, the brands are Piclin (Ppcosulphate sodium), Menoctyl (otilonium bromide), Sucramal O (sucralfate +oxetacaine), Pyridium (phenazopyridine) and Distaclor (cefaclor). The deal comes as Lupin has been exclusively marketing the brands in the Indian market since July 2021 under a distribution and promotion agreement.
“Growing urbanization and dietary changes are driving the demand for gastrointestinal and urology treatments in India,” said Rajeev Sibal, president, India region formulations, Lupin. “This acquisition strengthens our presence in India and bolsters our therapy pipeline. At Lupin, we are committed to empowering healthcare professionals in managing the increasing disease burden and improving the lives of patients significantly.”
Reference: Lupin Acquires Five Brands from Menarini. Lupin. September 22, 2023. Accessed September 25, 2023. https://www.lupin.com/lupin-acquires-five-brands-from-menarini/
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
